Elopag 50MG (Eltrombopag)
Product Name : Elopag 50
Generic Name : Eltrombopag
Formulation : Tablet
Available Pack Size : 14’s & 28’s
Available Strengths : 50 mg
Registrations : Bangladesh
Product Information
Elopag 50 (Eltrombopag) 50mg is an oral thrombopoietin (TPO) receptor agonist used to raise platelet counts in patients with Chronic Immune (Idiopathic) Thrombocytopenia (ITP), chronic Hepatitis C-associated thrombocytopenia, and Severe Aplastic Anaemia. It works by binding to and activating the human TPO receptor, stimulating the proliferation and differentiation of bone marrow progenitor cells into megakaryocytes, the cells responsible for producing platelets. Manufactured by Everest Pharmaceuticals Ltd., Bangladesh and globally supplied by Mediaid Pharmacy with worldwide shipping.
Basic Product Information of Elopag 50 (Eltrombopag) 50mg
| Brand Name | Elopag 50 (Eltrombopag) |
| Generic Name | Eltrombopag (as Eltrombopag Olamine) INN |
| Drug Class | Thrombopoietin (TPO) Receptor Agonist |
| Available Strength | 50mg |
| Formulation | Film-Coated Tablet |
| Pack Size | Available in Packs of 14 or 28 Tablets |
| Primary Indication | Chronic Immune Thrombocytopenia (ITP), Hepatitis C-Associated Thrombocytopenia and Severe Aplastic Anaemia |
| Regulatory Approvals | USFDA Approved (ITP, HCV-Associated Thrombocytopenia, Severe Aplastic Anaemia). EMA Approved. Carries an FDA Boxed Warning for hepatotoxicity. |
| Originator Brand | Promacta / Revolade by Novartis (developed by GSK) |
| Manufacturer | Everest Pharmaceuticals Ltd., Dhaka, Bangladesh |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Registration | Registered in Bangladesh |
| Storage Conditions | Store below 30 degrees Celsius. Keep in a dry place away from light and moisture. Keep out of the reach of children. |
How Elopag 50 (Eltrombopag) Works
Elopag 50 contains Eltrombopag, a small-molecule, orally bioavailable agonist of the thrombopoietin (TPO) receptor, also known as cMpl. Unlike natural thrombopoietin, Eltrombopag interacts with the transmembrane domain of the TPO receptor rather than the site used by the body’s own hormone, initiating signalling cascades that promote the proliferation and differentiation of megakaryocytes from bone marrow progenitor cells.
Because megakaryocytes are the cells responsible for producing platelets, activating this pathway increases platelet production and raises circulating platelet counts. This makes Elopag 50 valuable in conditions where platelet counts are low due to immune destruction, viral infection-related effects, or bone marrow failure, helping to reduce the risk of bleeding and, in some cases, allowing other necessary treatments to proceed safely.
Elopag 50 is taken as a once-daily oral tablet, with the dose individually titrated based on the patient’s platelet count response, and is not intended to normalise platelet counts to a “normal” range but rather to reduce bleeding risk to an acceptable level.
Indications for Elopag 50 (Eltrombopag)
Elopag 50 (Eltrombopag) is indicated for the following conditions:
|
Chronic Immune Thrombocytopenia (ITP) For patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. |
Hepatitis C-Associated Thrombocytopenia To allow the initiation and maintenance of interferon-based antiviral therapy in patients with chronic hepatitis C whose low platelet count would otherwise prevent treatment. |
|
Severe Aplastic Anaemia For patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy, or as first-line treatment in combination with standard immunosuppressive therapy. |
|
Benefits of Elopag 50 (Eltrombopag) 50mg
|
Standard-Dose Convenience As the standard starting strength for most adult patients with ITP or severe aplastic anaemia, Elopag 50 lets many patients begin treatment with a single tablet per day. |
Multi-Condition Coverage Approved for ITP, HCV-associated thrombocytopenia, and severe aplastic anaemia, Elopag 50 offers a versatile option across several distinct causes of low platelet counts. |
Oral Alternative to Injectable Therapies Unlike some other TPO receptor agonists that require injection, Elopag 50 is taken as a convenient oral tablet, once daily. |
|
Affordable Alternative to Promacta Elopag 50 contains the same active ingredient as Promacta (Revolade), at a significantly lower cost, making long-term platelet-support therapy more financially accessible. |
Companion Strength Available Mediaid Pharmacy also stocks Elopag 25 (25mg), allowing physicians to prescribe the exact starting or reduced dose needed for each patient. |
cGMP Certified Manufacturing Produced by Everest Pharmaceuticals Ltd. under cGMP-compliant manufacturing standards, helping ensure consistent quality, purity, and potency in every batch of Elopag tablets. |
How to Take Elopag 50 (Eltrombopag)
Route: Oral, taken on an empty stomach, at least 1 hour before or 2 hours after a meal.
Standard starting dose for ITP: 50mg (one 50mg tablet) once daily for most adult patients, then adjusted based on platelet count response, up to a maximum of 75mg per day (one 50mg tablet plus one 25mg tablet). Patients of East Asian ancestry or with hepatic impairment typically start at a lower 25mg dose, using the 25mg strength.
Standard starting dose for HCV-associated thrombocytopenia: Treatment typically starts at 25mg once daily (using the 25mg strength), titrated up as needed; once above 25mg, the 50mg strength can be used to reach the required dose, up to a maximum of 100mg per day.
Standard starting dose for severe aplastic anaemia: 50mg (one 50mg tablet) once daily for most adult patients, or a lower 25mg starting dose for patients of East Asian ancestry, titrated up based on platelet response to a maximum of 150mg per day (three 50mg tablets).
Avoid dairy and mineral supplements near dosing: Do not take Elopag 50 with dairy products or calcium-fortified foods and drinks, or with antacids or supplements containing calcium, iron, magnesium, aluminium, selenium, or zinc, within 4 hours before or after a dose, as these can significantly reduce absorption.
Missed dose: If a dose is missed, take the next dose at the normal scheduled time; do not double up doses.
Hepatic impairment: Use caution and start at a reduced dose (using the 25mg strength) in patients with hepatic impairment, given the increased risk of hepatotoxicity in this population.
Renal impairment: Plasma exposure may be reduced in patients with renal impairment; monitor closely and adjust dose as needed.
Paediatric use: Eltrombopag is approved for certain paediatric indications in some regions; follow specialist paediatric dosing guidance where relevant, as adult dosing does not directly apply to children.
Monitoring and Dosage Adjustments
Regular monitoring is essential throughout Elopag 50 treatment. Your physician will check liver function tests (ALT, AST, and bilirubin) before starting treatment, every 2 weeks during the dose adjustment phase, and monthly once a stable dose is established, with more frequent testing in patients receiving first-line therapy for severe aplastic anaemia. Monitoring also includes complete blood counts with platelet count, regularly during dose titration, peripheral blood smear examination for bone marrow changes, and periodic eye examinations, as TPO receptor agonists have been associated with cataract development in some studies. Report any yellowing of the skin or eyes, dark urine, unusual bleeding or bruising, or vision changes to your doctor immediately.
Drug Interactions and Important Information
Eltrombopag is extensively metabolised via CYP1A2 and CYP2C8 oxidation and UGT1A1/UGT1A3 glucuronidation, so caution is needed with medications that significantly affect these pathways. Eltrombopag also inhibits the OATP1B1 transporter and BCRP, which can significantly increase the plasma concentration of certain statins (such as rosuvastatin); a lower statin dose with careful monitoring is generally recommended when co-administered.
Elopag 50 can chelate with polyvalent cations found in antacids, dairy products, and mineral supplements, significantly reducing its own absorption if taken too close together; maintain the recommended separation from these products. Inform your physician of any history of liver disease, blood clots, or eye conditions such as cataracts before starting treatment. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Elopag 50.
Side Effects and Precautions
|
Common Side Effects Nausea Diarrhoea Fatigue Muscle aches Headache and dizziness Mild, transient elevations in liver enzymes |
Serious Warnings and Precautions Severe hepatotoxicity, including cases of significant liver injury requiring discontinuation. Hepatic decompensation in HCV-coinfected patients on interferon-based therapy. Thrombotic and thromboembolic events, including venous and arterial events. Increased risk of bone marrow reticulin fibre deposition, a class effect of TPO receptor agonists. Not indicated for MDS, due to observed risk of progression to acute myeloid leukaemia. |
Who Should Use Elopag 50 (Eltrombopag)?
Elopag 50 is suitable for patients with chronic Immune Thrombocytopenia who have had an inadequate response to first-line treatments, patients with chronic Hepatitis C-associated thrombocytopenia who need platelet support to begin or continue antiviral therapy, and patients with severe aplastic anaemia, either as first-line combination therapy or after inadequate response to immunosuppressive treatment. It is prescribed by haematologists and hepatologists experienced in managing platelet disorders. A thorough medical assessment including baseline liver function, complete blood counts, and cardiovascular risk evaluation is required before initiating treatment.
Manufacturer: Everest Pharmaceuticals Ltd.
Everest Pharmaceuticals Ltd. is a vertically integrated pharmaceutical company based in Dhaka, Bangladesh, focused on complex, technology-driven specialty medicines across oncology, haematology, nephrology, and virology. Operating under Bangladesh’s TRIPS/Doha Declaration exemption for least-developed countries, Everest manufactures advanced generics such as Elopag under cGMP-compliant standards, with the stated mission of making high-cost, life-saving medicines accessible and affordable to patients around the world. Elopag 50 is one of Everest’s specialty haematology products, offering a bioequivalent alternative to Promacta (Revolade) at a fraction of the cost.
Global Supplier: Mediaid Pharmacy with Worldwide Shipping
Mediaid Pharmacy is a trusted global supplier of specialty medications. We ensure Elopag 50 (Eltrombopag) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.
Why Choose Elopag 50 (Eltrombopag) from Mediaid Pharmacy?
Elopag 50 represents a well-established, oral option for patients managing low platelet counts due to ITP, hepatitis C, or aplastic anaemia. As the generic equivalent of Promacta (Revolade), it delivers the same active ingredient, Eltrombopag, with the same proven TPO receptor agonist mechanism at a dramatically more affordable price. Manufactured by Everest Pharmaceuticals Ltd. under cGMP-compliant standards and distributed globally by Mediaid Pharmacy, Elopag 50 gives patients worldwide access to effective platelet-support therapy without the financial burden of brand-name alternatives. Paired with the companion Elopag 25 strength, physicians can prescribe the exact dose needed at every stage of treatment. For patients and physicians seeking a proven, affordable, and accessible Eltrombopag option with worldwide delivery, Elopag 50 from Mediaid Pharmacy is the trusted choice.
Frequently Asked Questions About Elopag 50 (Eltrombopag)
What is Elopag 50 (Eltrombopag) used for?
Elopag 50 (Eltrombopag) is used to raise platelet counts in patients with chronic Immune Thrombocytopenia (ITP) who have not responded adequately to other treatments, patients with chronic Hepatitis C-associated thrombocytopenia who need platelet support to receive antiviral therapy, and patients with severe aplastic anaemia. It works by stimulating the bone marrow to produce more platelets.
How should I take Elopag 50 (Eltrombopag)?
Elopag 50 is taken orally, once daily, on an empty stomach, at least 1 hour before or 2 hours after a meal, and away from dairy products or mineral supplements. Most adult patients with ITP or severe aplastic anaemia start on one 50mg tablet daily, while HCV-associated thrombocytopenia typically starts at a lower 25mg dose. Always follow your physician’s exact instructions.
What pack sizes is Elopag 50 available in?
Elopag 50 is available in packs of 14 or 28 film-coated tablets, each containing 50mg of Eltrombopag. A companion 25mg strength (Elopag 25) is also available for patients who need a lower starting or maintenance dose.
Is Elopag 50 the same as Promacta (Eltrombopag by Novartis)?
Yes. Elopag 50 is the generic equivalent of Promacta (also known as Revolade in some markets). Both contain the same active ingredient, Eltrombopag, and work through the same TPO receptor agonist mechanism. Elopag 50 is manufactured by Everest Pharmaceuticals Ltd. in Bangladesh and offers the same clinical mechanism at a significantly lower cost.
What are the side effects of Elopag 50 (Eltrombopag)?
Common side effects include nausea, diarrhoea, fatigue, muscle aches, and headache. Elopag 50 carries a boxed warning for severe liver injury, and in HCV patients on interferon-based therapy, an increased risk of hepatic decompensation. Always consult your physician for a complete assessment of your individual risks and benefits before starting treatment.
Can Elopag 50 be used with other medications?
Elopag 50 can significantly increase the levels of certain statins, so a lower statin dose with monitoring may be needed. Avoid taking Elopag 50 close to dairy products, antacids, or mineral supplements containing calcium, iron, magnesium, aluminium, selenium, or zinc, as these reduce its absorption. Always inform your physician of all medications, supplements, and herbal products you are taking before starting Elopag 50.
Is Elopag 50 (Eltrombopag) safe during pregnancy or breastfeeding?
Please consult your physician before starting treatment if you are pregnant, planning to become pregnant, or breastfeeding, so that the potential risks and benefits can be discussed for your individual situation, as data in these populations are limited.
Can I order Elopag 50 (Eltrombopag) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Elopag 50 (Eltrombopag) globally with worldwide shipping. Contact us via WhatsApp, phone, or WeChat at +8801773428128 or email us at info@mediaidpharmacy.com to enquire about pricing, availability, and delivery to your country.
Order Elopag 50 (Eltrombopag) with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
